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Abstract
Background: Naloxone has been evidenced widely as a means of reducing mortality resulting
from opiate overdose, yet its distribution to drug users remains limited. However, it is drug users
who are most likely to be available to administer naloxone at the scene and who have been shown
to be willing and motivated to deliver this intervention. The current study builds on a national
training evaluation in England by assessing 6-month outcome data collected primarily in one of the
participating centres.
Methods: Seventy patients with opioid dependence syndrome were trained in the recognition and
management of overdoses in Birmingham (n = 66) and London (n = 4), and followed up six months
after receiving naloxone. After successful completion of the training, participants received a supply
of 400 micrograms of naloxone (in the form of a preloaded syringe) to take home. The study
focused on whether participating users still had their naloxone, whether they retained the
information, whether they had witnessed an overdose and whether they had naloxone available and
were still willing to use it in the event of overdose.
Results & Discussion: The results were mixed - although the majority of drug users had retained
the naloxone prescribed to them, and retention of knowledge was very strong in relation to
overdose recognition and intervention, most participants did not carry the naloxone with them
consistently and consequently it was generally not available if they witnessed an overdose. The
paper discusses the reasons for the reluctance to carry naloxone and potential opportunities for
how this might be overcome. Future issues around training and support around peer dissemination
are also addressed.
Conclusion: Our findings confirm that training of drug users constitutes a valuable resource in the
management of opiate overdoses and growth of peer interventions that may not otherwise be
recognised or addressed. Obstacles have been identified at individual (transportability, stigma) and
at a systems level (police involvement, prescription laws). Training individuals does not seem to be
sufficient for these programmes to succeed and a coherent implementation model is necessary.
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Background
Fatal heroin overdose is a significant cause of mortality for
injecting drug users (IDUs). Between 1997 and 2002, opi-
ates (including heroin, morphine and methadone)
accounted for 6,194 deaths in England and Wales [1]. The
mortality rate among opioid drug users is known to be sig-
nificantly elevated - approximately 2-3% of heroin users
die each year and these rates are between six and twenty
times higher than those expected among non-drug using
peers of the same age and gender [2]. This pattern is found
worldwide and in many countries (including the UK)
deaths resulting from drug misuse (predominantly opiate
overdose) account for as many deaths as road traffic acci-
dents among males [3]. Excess mortality is also well recog-
nised among the sub-population of opiate addicts newly
released from prison [4,5]. During the first and second
week after discharge, male prisoners were found to be
twenty nine times more likely to die, while in females the
rate was sixty nine times higher than in the age-matched
general population [4].
The majority of opiate-related deaths result from acciden-
tal overdose, with at least 50% of opiate users having
experienced a non-fatal overdose at some point during
their lives [6,7]. Sequelae of non fatal overdose are not
rare and represent an additional public health burden
[8,9]. Published data has been limited in quantifying the
sequelae associated with non fatal overdose. Peripheral
neuropathy (resulting from prolonged pressure when
unconscious) and pulmonary complications (such as
oedema and pneumonia) are the most common compli-
cations reported. Rhabdomyolysis accompanied by renal
failure and nerve palsy are rare. Cardiovascular complica-
tions and cognitive impairments have also been docu-
mented. Indirect injuries include physical injuries
sustained when falling (while overdosing), burns and
assault while unconscious[8].
Research has shown that a high proportion of overdoses
are witnessed yet often medical help is not sought or is
sought too late [10]. In non-fatal heroin overdoses, emer-
gency services are only contacted on 30-50% [11] of cases,
with concerns of police involvement acting as a significant
barrier to witnesses accessing emergency services [12]. The
presence of bystanders such as peers or family has been
seen as an opportunity for intervention in an overdose sit-
uation, whilst awaiting the arrival of emergency medical
care, based on the recognition that overdose is a process
not an event [13]. Harm reduction strategies in this area
were first proposed in 1996 to prevent opioid-related
deaths through the provision of the opioid antagonist
naloxone [14]. These programmes started in Europe, pro-
gressed to Australia and the United States where naloxone
was first distributed in 1999 through programmes operat-
ing in Chicago [15] and San Francisco [16]. Barriers for
implementation were noted in areas such as prescription
drug laws and drug users' misconceptions about naloxone
[12,17].
Naloxone is an opioid antagonist that reverses the effects
of opioids in the brain and restores breathing. Its use is
associated with transient withdrawal symptoms such as
gastro-intestinal disorders, irritability, tachycardia, shiver-
ing, sweating and tremor. Most events described in pre-
hospital administration of naloxone are not serious
[18,19]. A small but consistent rate of seizures, pulmo-
nary oedema and arrhythmias has been described after
postoperative administration. These reports are rare and
seemed to be associated with pre-existing cardiac abnor-
malities and drug interactions, and typically involve sig-
nificantly higher dose levels than those used in peer
overdose interventions [11,20]. Naloxone induced hyper-
tension has also been reported and is possibly related to
catecholamine release[20]. Reports from the training pro-
grammes have documented life saving events through
peer administration without observed side effects, possi-
bly as a result of the lower doses that are typically used in
overdose reversal situations [14,21].
Naloxone training and distribution programmes for drug
users have provoked controversy among the medical pro-
fession and policy makers. Those in favour of issuing
naloxone maintain that by training potential witnesses
and increasing availability (by relaxing prescription laws)
there will be a positive public health impact by reducing
the number of drug related deaths among this population
[5]. For instance, the study led by Marxwell et al [15]
showed a negative correlation between the upward trend
of opioid overdose deaths reported by the medical exam-
iner's office and the implementation of the overdose pre-
vention programme in Cook County. Those calling for
caution [22,23], maintain that there is a potential for
inappropriate use of naloxone by this population with the
increased risk of untoward events that could raise issues of
liability. So far, inappropriate use of naloxone has not
been reported in evaluation studies.
There has been an ongoing debate as to whether the avail-
ability of naloxone might promote a 'false sense of secu-
rity' resulting in a subsequent increase in heroin use. In
fact, what limited evidence exists suggests the opposite.
Seal et al [16] found that there was a decrease in use of
heroin among participants six months after the training;
this was attributed to an increase in self efficacy and more
insight in relation to personal safety and health obtained
during the programme and also resulting from the fright-
ening and aversive effects of witnessing an overdose expe-
rienced by the 'rescuer' [15]. Emergency services were
found to be contacted less often in those trained in the use
of naloxone (10-31%) [11,16,24] in comparison to wit-
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nesses of an opioid overdose that did not involve training
programmes (30-50%) [11]. This has been associated
with fears of arrest [3], an outstanding warrant [11] and
increased confidence in reviving the victim [16]; the con-
cern is that these may reduce subsequent engagement
with treatment services among overdose victims. How-
ever, the majority of studies conducted to date provide lit-
tle support for the proposed iatrogenic effects of naloxone
distribution.
Well designed research into the practice of overdose pre-
vention training and naloxone distribution is limited.
Outcomes of established programmes have been meas-
ured through the replacement of the naloxone once the
supply was used. Studies are subject to self-report bias and
lack adequate corroborating evidence. Longitudinal for-
mal evaluation of the cohorts trained has been challeng-
ing due to lack of statistical power, high attrition rates,
and lack of resources [25,26]. To date only one study has
evidenced the effectiveness of overdose training and dis-
tribution programmes across different sites in the United
States, which despite its limitations has encouraging
results. The study compared knowledge about overdose
recognition, administration of naloxone and personal
competence among groups that only differed on whether
they received training on these topics. The study reported
that training programmes improve recognition and
response to overdoses in the community.
In the current study, we present the results of an evalua-
tion of a cohort of patients followed up for six months
after the initial training and immediate supply of
naloxone. Training and three month outcomes are
described in Strang et al [27], and the current paper
extends the evaluation to the 46 patients successfully fol-
lowed up at the 6-month point, primarily from the Bir-
mingham site but also including the four follow-ups done
by the London team. The aim of the study was to assess
the effectiveness of training clients in overdose awareness
and response, in testing the durability and longevity of
acquired knowledge about recognising and intervening in
opiate overdose. Additionally, the study assessed whether
the clients had retained their naloxone prescription and if
so where it was kept and how available it had been in
overdose contexts.
Methods
Sample characteristics
Between January 2006 and January 2007, 70 patients
diagnosed with opioid dependence syndrome were
trained in the recognition and management of overdoses
in Birmingham (n = 66) and London (n = 4). Out of 70
patients, 65% of the sample was followed up over a 6-
month period (n = 46). For details of the training and dis-
tribution programme, and the characteristics of the full
sample trained see Strang et al (2008). Participants in the
cohort were over the age of 18 and had been attending
either a detoxification centre or one of six community
drug treatment teams at the time of the training session.
After the training programme described in Strang et al [27]
participants received a supply of 400 micrograms of
naloxone (minijet) to take home, on successful comple-
tion of the training.
Outreach efforts to recruit participants for the follow-up
evaluation included flyers, word of mouth and needle
exchange services. Participants were followed up and
reinterviewed three months and six months after the train-
ing event, if they were available. Interviews were per-
formed over the phone or in face-to-face interviews by one
of the authors of the paper (RLG). The interview consisted
of a structured questionnaire assessing current use of
drugs, whether the trainee had experienced or witnessed
an overdose since receiving the supply of naloxone, and if
so, what actions were taken. Questionnaires also aimed to
measure retention of the knowledge gained during the
training on recognition and management of overdoses.
Dissemination of information (to relatives/partners/
friends) was also tested as well as whether participants
were still in possession of the naloxone. On completion of
follow up interviews, participants were remunerated with
a £10 voucher. Consent was sought from all participants
that entered the study.
Summary of Training Programme
All participants received overdose prevention training by
staff (n = 78) that was provided onsite in treatment agen-
cies and the programme involved one of the authors, who
prescribed the naloxone on completion of the training
(RLG). Opiate users were trained either individually or in
small groups (3-10 people) and each training session
lasted approximately thirty minutes. Prior to the start of
the training a questionnaire was distributed to partici-
pants assessing their overdose knowledge and experi-
ences. Overdose training included recognising and
discussing the causes of opiate overdose, how to avoid an
opiate overdose, signs of an opiate overdose and what to
do in this situation. Thus, the initial phase of the training
was a harm reduction intervention about overdose recog-
nition and intervention based on placing the individual in
the recovery position and calling for an ambulance. The
second phase addressed when and how to use naloxone.
The naloxone training included information on naloxone,
education about appropriate responses to opiate overdose
and instructions on naloxone administration.
It was made clear to participants that naloxone was not an
alternative to emergency medicine and that an ambulance
should be called prior to the administration of naloxone.
A dummy of the naloxone minijet was available to dem-
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onstrate and practice how to assemble and use the device
during the training session. Participants completed post-
training questionnaires which were identical to the one
given prior to the training, to test changes in knowledge
and reported in Strang et al [27]. These questionnaires
tested their knowledge about the recognition of overdoses
and their management. Upon completion of the overdose
prevention training, trainees were issued with one dose of
naloxone 400 micrograms minijet with a needle and writ-
ten information summarizing overdose recognition and
revival steps by a doctor (psychiatrist or general practi-
tioner).
Measurement of knowledge
Participants were asked the same questions at each of four
time points - immediately prior to and on completion of
the training; at three month follow-up and at 6-month
follow-up. These focused on:
1. Risk factors for overdose with seven optional answers:
(i) using too much heroin, (ii) using heroin alongside
other substances, (iii) change in drug purity, (iv)
change in tolerance, (v) switching from smoking to
injecting heroin, (vi) using heroin alone and (vii)
using in unfamiliar places.
2. Signs of an overdose with eight optional answers: (i)
blood shot eyes, (ii) shallow breathing, (iii) turning
blue, (iv) blurred vision, (v) unrousable/loss of con-
sciousness, (vi) fitting, (vii) deep snoring and (viii)
pinned pupils.
3. Actions to take in the event of an overdose with eleven
optional answers: (i) call an ambulance, (ii) stay with
the person until they come round, (iii) walk the per-
son around the room, (iv) inject saline solution, (v)
give stimulants by mouth, (vi) slap or shake the per-
son, (vii) shock the person with cold water, (viii) per-
form mouth to mouth resuscitation, (ix) place the
person in recovery position, (x) administer naloxone
and (xi) stay with the person until the ambulance
arrives.
All of the options for risk factors were real risks and so a
total score was created out of eight. However, for the other
two scales, the options consisted of both correct and
incorrect options so the totals represent the number of
correct items endorsed (the original questions are
included as Appendix 1).
Results
Seventy participants took part in the study and were
trained in recognition and management of overdoses six
months prior to the evaluation. Respondents were pre-
dominantly male (n = 54, 77%) with a mean age of 34.2
years (± 8.0 years). Of this original sample, 58 people
(82.8%) were successfully contacted at the three-month
follow-up point and 49 (70.0%) at the 6-month follow-
up. However, the sample examined in detail below are
those who were interviewed at all three time points (n =
46). This constitutes 65.7% of the cohort originally
trained. This group consisted of 35 males and 11 females
and had a mean age of 35.0 years.
13 (28.9%) of the group reported that they had ever had
an opioid overdose (ranging from 1-6, a total of 34 over-
doses in total), while only one person had overdosed in
the six months since the initial training. On that occasion
naloxone was administered by the ambulance crew and
the person had a full recovery. In contrast, nine individu-
als reported witnessing a total of 16 overdoses in the 6-
month period since the training event (range = 1-4 over-
doses witnessed). The response to these events is dis-
cussed below.
Knowledge and awareness change following training
Indicators of opiate overdose
Figure 1 below shows the change in total scores on accu-
rate reporting of signs of overdose from pre- to post-train-
ing and then to follow-up interviews:
In knowledge of signs of overdose, there is a significant
improvement from a baseline score of 5.5 out of 7 to 6.7
(t = 5.02, p < 0.001) immediately after the training. In
contrast, the reductions in knowledge scores between
post-training and three-month follow-up (t = 1.48, p =
0.15), and from three months to six-months post-training
follow-up (t = 1.95, p = 0.06) were not statistically signif-
icant. There is an overall improvement in average knowl-
edge from baseline (mean = 5.5 out of 7) to follow-up
(mean = 6.0 out of 7) that is statistically significant (t =
2.25, p < 0.05) suggesting that knowledge of overdose
signs is retained over time.
Changes in recognition across the four time points (pre- to post-training, three months and six months)Figur  1
Changes in recognition across the four time points 
(pre- to post-training, three months and six months).
5.5
6.7
6.4
6
Number of correct responses
pre-training post-training 1 month follow-up 6 month follow-up
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Actions to take in overdose events
As shown in Figure 2 below, there is a similar improve-
ment in knowledge of actions to be taken.
There was a significant increase in the number of appro-
priate actions to taken identified from pre-training to
post-training (5.6 to 8.9 out of 11; t = 7.60, p < 0.001).
There were further (non-significant) increases in the aver-
age correct scores from post-training to three month fol-
low-up (mean score of 8.9 to 9.2; t = 0.67, p = 0.51), and
again from three months follow-up to six months (mean
increase from 9.2 to 9.3; t = 1.03, p = 0.31). Overall, there
was a marked increase in knowledge from baseline to 6-
months (from a mean score of 5.6 to 9.3, t = 9.62, p <
0.001). Thus, across the two scales measured at both time
points, clients showed consistently improved levels of
knowledge.
Naloxone possession and retention
At the three month follow-up, 40 of the 46 clients
(87.0%) reported that they still had the naloxone that
they were given at the end of the training session. Of the
remaining, 2 reported that they had lost it and 4 were not
sure. At the six-month follow-up, 37 of the 46 participants
still had the naloxone (80.4%), 3 had lost it, one had
thrown it away because the minijet had passed its 'expiry
date', one reported that it had broken, one returned it to
their treatment worker when they stopped using heroin,
and one had thrown it away when they started inpatient
detoxification treatment. The data for the other two cases
were missing. However, of the 37 people who retained
their naloxone, seven did not keep it at home - thus for 30
of 37 clients (81.0%), the naloxone could only be used if
the overdose occurred in their own home.
Although no differences in pre-training knowledge, those
who still had their naloxone at the six-month follow-up
point, reported significantly higher mean post-training
knowledge of signs indicative of opioid overdose (see
Table 1):
Clients who had higher knowledge scores after the train-
ing were more likely to still have the naloxone minijet 6
months later, and this difference was significant for their
knowledge of overdose signs. In total, 16 clients reported
that they trained others in how to use naloxone, but this
was not related to their own knowledge or awareness.
What happened in the event of overdose after the training?
As indicated above, a total of nine individuals reported
that they witnessed 16 overdoses in the 6 month period
after the training. Seven of the nine people who witnessed
overdoses reported that they still possessed their naloxone
at the time of the witnessed overdose, of whom four
reported that they kept it at home, two in their bag and for
one case this information was missing. The reasons for
non-use were not related to failing to recognise that an
overdose was taking place - all 9 reported that they felt
confident that they would recognise an overdose. The fol-
lowing responses were given as indicators of overdose at
the time:
• shallow breathing (4/9)
• blue lips (5/9)
• pinned pupils (2/9)
• unresponsive to pain (1/9)
• unconscious (5/9)
In relation to the actions taken during the witnessed over-
doses, none of the individuals reported taking any inap-
propriate action that could have endanger the victim's
situation (e.g. walking the person around the room, injec-
tion of saline solution, administration of oral fluids,
putting the person in a bath). Actions taken during the
overdose were in agreement with the training received, for
instance witnesses:
• Called an ambulance (3/9)
• Placed the person in the recovery position (2/9)
• Stayed with the person until they came round (2/9)
Changes in actions to be taken from pre to post-training and in each follow-up for actions in esponse to overdoseFigur  2
Changes in actions to be taken from pre to post-
training and in each follow-up for actions in response 
to overdose.
5.6
8.9
9.2 9.3
Number of correct responses
pre-training
post-training
1 month follow-up
6 month follow-up
Table 1: Knowledge as a predictor of naloxone retention
Lost (n = 9) Retained (n = 37) T, sig
Post - risks 4.9 6.1 1.25
Post - signs 5.3 7.1 3.78***
Post - actions 7.1 9.3 1.68
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• Stayed with the person until the ambulance arrived
(2/9)
• Checked airways for obstruction (3/9)
• Checked breathing (4/9)
• Performed mouth to mouth resuscitation (2/9)
• Checked the pulse (3/9)
Out of the 16 people who had overdoses that were wit-
nessed by participants in the study, one was already dead
when found, six survived and data was missing for the
rest. From those who survived, naloxone was used in three
cases by the ambulance crew with no reports of adverse
reactions and two individuals were admitted to hospital.
From those that witnessed overdoses, five did not use
their supply of naloxone, and data is missing from the
other four cases. In other words, in those five cases in
which data is available, none used the naloxone pre-
scribed after the training. The reasons given for this were:
• Naloxone was lost (1/5)
• Not wanted to be found with injecting equipment in
place of work (1/5)
• Person was 'clean' (no longer using illicit substances)
and did not want to carry injecting material (2/5)
• Not appropriate as person already dead when found
(1/5)
• Data missing (4/9)
Discussion
The results of this study suggest that training opiate users
in the recognition and management of opiate overdoses
has a significant impact on their awareness, knowledge
and confidence, and increased their likelihood to inter-
vene in high risk situations. In areas such as identification
of risk factors/signs of opiate overdose, and the knowl-
edge of appropriate actions that need to take place, the
comparison of pre-training scores and scores six months
after the training demonstrates consistent retention of
knowledge, with only slight deterioration in awareness of
signs although these remained above the baseline level.
The improvements in knowledge post-training for appro-
priate actions could be related with the rehearsal and con-
solidation of information that had taken place in each of
the follow up points throughout the study; showing
potential opportunities for refresher courses in the target
population after the initial training.
In addition, the majority of individuals trained still pos-
sessed the naloxone six months later suggesting a commit-
ment to the process of peer education and intervention. It
is intriguing to note that knowledge reported at the end of
the training appeared to predict whether people will
retain the naloxone, suggesting that those clearest about
when and how to use naloxone are also those who are
most likely to retain the minijet. While most overdoses
occur in residential settings [10], we cannot assume that
this is always the home of the person to whom the
naloxone is prescribed. Thus, the transportability of the
naloxone and the willingness of the recipient to carry it
are key to the success of naloxone distribution schemes. In
our study, most of the individuals that kept naloxone did
so at home, and from those witnesses for whom informa-
tion is available, none of them was in possession of the
medication when the overdose occurred. This appears to
contradict the reported willingness to use naloxone
reported in the earlier London study [28]. Two reasons for
the reluctance to carry naloxone are perceived stigma and
fear of police engagement, and the awkwardness of carry-
ing something bulky and unwieldy. It would be antici-
pated that improvements in product development
supplemented by increased awareness of naloxone pro-
grammes in target areas would break down some of these
barriers to trainees carrying their naloxone. The data avail-
able from some of the witnesses suggest that they
wouldn't carry naloxone with them due to issues related
with stigma (not wanting to be found with injecting mate-
rial if searched, the association between injecting material
and using illicit drugs, etc) and their drug taking status
(being 'clean' or in recovery as opposed to actively using
illicit substances). This may suggest that willingness alone
is not sufficient for this intervention and users have to be
confident that the police and ambulance services will not
have detrimental reactions to them having naloxone. An
additional factor that could have biased the results in this
direction could be related to the recruitment of the cohort.
Participants were recruited exclusively from treatment set-
tings and those followed up were mostly patients dis-
charged after residential opioid detoxification. Issues
related with stigma in carrying naloxone in this popula-
tion could have been enhanced by a perceived conflict
between their recovery pathway after detoxification - and
moving away from drug-using peers - and the 'conflicting'
desire to carry a medication in the event of witnessing an
opioid overdose situation. While this is in practice a good
location in which to access and train drug users, their own
abstinence-oriented treatment plans may be a barrier to
successful intervention and to their willingness to carry
naloxone. The use of treatment populations generally
present different challenges in understanding the scope
for naloxone use by peers that are partly shaped by the
social networks of treated clients and their levels of ongo-
ing exposure to drug use. An important development in
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our knowledge of naloxone utility will be to understand
the relative impact of programmes that target in treatment
compared to out of treatment populations of heroin users.
In terms of formulation and type of prescription, the rela-
tively bulky mechanism of a minijet may make this unat-
tractive to users and the appearance of a needle may be a
psychological barrier to former users who have stopped
using. Further investigation of other options, such as nasal
sprays or more discrete presentations may be beneficial in
overcoming these barriers to naloxone availability. There
have been trials in which intranasal naloxone was used as
first line intervention in prehostpital setting [29,30]. Evi-
dence is still lacking in relation to the effectiveness, safety
and utility of this route of administration for naloxone
[5]. Most crucially, user group involvement in the dissem-
ination process may assist in addressing each of these con-
cerns.
The importance of peer group work is emphasised by the
findings around 'secondary training'. A third of the sam-
ple reported that they had trained significant others in
overdose recognition and management, this being an
important element in the chain of knowledge triggered by
the study, and which is informing the current work we are
doing which involves peers in the delivery of the initial
training package. Previous studies [12,17] suggest that
issues related to the presence of the police would deter
individuals from contacting the ambulance services as
part of the actions taken when facing an overdose situa-
tion. This study was not designed to elicit this particular
aspect; however, the available data suggests that from the
16 overdoses witnessed, police presence was reported in
one occasion after contacting emergency services. It is crit-
ical that both the reality of police involvement is
addressed through inter-agency working and that the per-
ception of police involvement in overdose is also
addressed through treatment services and user involve-
ment groups.
The study is limited by the small sample size, recruitment
biases, missing data and the problems associated with
study attrition. It is not known what the rates of knowl-
edge or naloxone retention were in the group that could
not be contacted for this study, and the use of primarily
one location means that there may also be local effects
relating to the nature of the training and the group
accessed in this one location, a UK city with a low rate of
intravenous drug use. Similarly, the study is entirely reli-
ant on self-report and we have not been able to corrobo-
rate the reports around the witnessed overdose events
reported. Accessing trainees after the event has proved to
be difficult and we had to rely on brief phone conversa-
tions in some cases, resulting in large amounts of missing
information from a few participants.
In summary, our findings confirm previous reports that
the training of possible bystanders to opiate overdose
constitutes a valuable resource in the assessment and
management of opiate overdoses that may not otherwise
be recognised or addressed. This has been demonstrated
by the increased levels of knowledge retention associated
with high confidence and willingness to keep the medica-
tion six months after the training took place. Obstacles
have been identified at individual and at a systemic level.
For instance, there are issues of transportability of
naloxone related to its formulation and also perceived
stigma (the association of this drug with the 'active user of
illicit substances' status). This is related with overpower-
ing fears of being searched by the police whilst in posses-
sion of naloxone, as well as police involvement when the
emergency services are contacted. Witnesses' concerns of
being treated as responsible parties if naloxone is used at
the scene when an overdose takes place, have been
reduced by education about prescription laws during the
training. The reclassification of naloxone under article 7
of Prescription Only Medicines Order in the UK, allows
the administration of naloxone by injection by anyone for
the purpose of saving a life in an emergency. However UK
laws still hold naloxone as a prescription medication that
requires a face to face encounter for the medication to be
legally prescribed on a 'patient named bases'. As stated
above, a third of the sample trained significant others in
the recognition and management of an opiate overdose.
According to current prescription laws this subpopulation
cannot be provided directly with naloxone. Innovative
training schemes [31] have trained opioid users with sig-
nificant others ('buddies') increasing the opportunities to
prescribe directly to patients with the involvement of
those that care for them (potential witnesses). This strat-
egy elegantly uses the current legal framework as a bridge
rather than hindrance towards naloxone distribution by
prescribing to the patient accounting for emergency use by
the significant other. Whilst this paper is being written,
the UK government started to launch a pilot scheme
through the National Treatment Agency [32] by which
this practice is being encouraged countrywide.
Consequently, training individuals does not seem to be
sufficient for these programmes to succeed and a more
systemic approach is necessary. Changes in prescription
laws, increasing education and communication between
the police force, emergency services and opiate users and
reducing the stigma that prevails in these areas, are essen-
tial ingredients for these programmes to move forward.
The complexities of these changes mean that existing
schemes should be innovative and in constant develop-
ment to progress within the current constraints.
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